Previous 10 | Next 10 |
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the...
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busine...
Investors walked away from shares of Minerva Neurosciences (NASDAQ: NERV) and Axsome Therapeutics (NASDAQ: AXSM) last month. OK, it was more of a sprint. The stock prices of the pair have fallen 33% and 29%, respectively, since the beginning of September, but each tumbled for a different...
Shares of Minerva Neurosciences (NASDAQ: NERV) tumbled more than 28% today after the company provided an update on the status of three pipeline assets. The biggest news was that a phase 3 trial evaluating the company's lead drug candidate, MIN-101 (roluperidone), was delayed after a cyberatt...
Gainers: Teekay Offshore Partners L.P. (NYSE: TOO ) +32% . BioCardia ( OTCQB:BCDA ) +25% . Roan Resources (NYSE: ROAN ) +21% . Conformis (NASDAQ: CFMS ) +18% . Constellation Pharmaceuticals (NASDAQ: CNST ) +15% . Pintec Technology Holdings (NASDAQ: PT ) +13% . Geron Corporation...
Minerva Neurosciences (NASDAQ: NERV ) -25% following delay in schizophrenia drug results. More news on: Minerva Neurosciences, Inc., Pacific Coast Oil Trust, TD Ameritrade Holding Corporation, Stocks on the move, Read more ...
Minerva Neurosciences (NASDAQ: NERV ) -27.8% pre-market after disclosing a delay in issuing top-line results for its roluperidone treatment for negative symptoms in schizophrenia. More news on: Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Company to host conference call at 8:30 a.m. today (dial-in information below) WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CN...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...